Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of “Buy” from Analysts

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has been assigned an average rating of “Buy” from the fourteen analysts that are covering the firm, Marketbeat.com reports. Fourteen equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $125.93.

Several research firms have recently weighed in on AXSM. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Axsome Therapeutics in a report on Monday, November 25th. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $130.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, November 12th. Finally, Robert W. Baird upped their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th.

Axsome Therapeutics Trading Up 0.1 %

AXSM opened at $87.01 on Friday. The firm’s fifty day moving average is $93.69 and its two-hundred day moving average is $88.25. The firm has a market cap of $4.22 billion, a PE ratio of -13.32 and a beta of 1.18. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $105.00. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. During the same quarter last year, the business posted ($1.32) EPS. Equities research analysts anticipate that Axsome Therapeutics will post -4.6 EPS for the current year.

Institutional Trading of Axsome Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. bought a new position in shares of Axsome Therapeutics in the 2nd quarter valued at about $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Axsome Therapeutics in the 2nd quarter valued at about $47,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after purchasing an additional 318 shares during the last quarter. Moors & Cabot Inc. bought a new position in Axsome Therapeutics during the third quarter worth about $200,000. Finally, Whalen Wealth Management Inc. acquired a new position in Axsome Therapeutics during the third quarter worth approximately $236,000. 81.49% of the stock is owned by institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.